Astrazeneca’s revenue surges as pipeline investments pay off Pharma Pascal Soriot, chief executive officer of AstraZeneca, said: "Astrazeneca had a very strong start in 2024 with substantial total revenue growth of 19 per cent in the first quarter.
Angle agrees deal with Astrazeneca for tech to kill cancer cells Pharma This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment.